Australia's drugs watchdog said Saturday it had ordered the recall of the anti-inflammatory medication Prexige after it was linked to two deaths.
The Therapeutic Goods Administration (TGA) said Australia was the first country to withdraw the drug, which is in the same class of pharmaceuticals as Vioxx, withdrawn by manufacturer Merck in 2004.
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a joint. Osteoarthritis can affect any joint of the body.
Advertisement
Technically called lumiracoxib, Prexige is produced by the Switzerland-based company Novartis AG, which said it had contacted health authorities in 50 countries where the drug is sold about the withdrawal.
The move followed a review of eight cases where people suffered severe liver damage after using the drug. Two of those people died and another two required liver transplants.
![Dysmenorrhea]( "Dysmenorrhea")
Dysmenorrhea, menstrual cramps or painful periods is the commonest menstrual disorder. The causes are varied. Treatment aims at providing pain relief.
"As a result of those case reports we have taken this straight to our drug safety committee who met yesterday," said Rohan Hammett, the TGA's principal medical adviser.
"They recommended that it immediately be deregistered."
Australia was the first country to recall the drug, Hammett said.
Prexige is taken by about 60,000 people in Australia and is prescribed for osteoarthritis, post-operative pain, pain related to dental procedures and painful menstruation.
The TGA has recommended people taking Prexige seek an alternative medication and have liver function blood tests. It is a non-steroidal anti-inflammatory drug, technically called a Cox-2 inhibitor.
Another Cox-2 inhibitor, Vioxx or Rofecoxib, was voluntarily recalled by manufacturer Merck in 2004 due to adverse health conditions in patients taking it.
"Regulators around the world have been watching this class of drugs very closely since Vioxx and hence we've acted very quickly," Hammett said.
Novartis said it supported the decision.
"Cleary, patient safety is of the utmost importance," said Nick Kurstjens, the company's chief scientific officer for Australia.
Source: AFP
LIN/C
Dysmenorrhea
Dysmenorrhea, menstrual cramps or painful periods is the commonest menstrual disorder. The causes are varied. Treatment aims at providing pain relief.
Advertisement
"As a result of those case reports we have taken this straight to our drug safety committee who met yesterday," said Rohan Hammett, the TGA's principal medical adviser.
"They recommended that it immediately be deregistered."
Australia was the first country to recall the drug, Hammett said.
Prexige is taken by about 60,000 people in Australia and is prescribed for osteoarthritis, post-operative pain, pain related to dental procedures and painful menstruation.
The TGA has recommended people taking Prexige seek an alternative medication and have liver function blood tests. It is a non-steroidal anti-inflammatory drug, technically called a Cox-2 inhibitor.
Another Cox-2 inhibitor, Vioxx or Rofecoxib, was voluntarily recalled by manufacturer Merck in 2004 due to adverse health conditions in patients taking it.
"Regulators around the world have been watching this class of drugs very closely since Vioxx and hence we've acted very quickly," Hammett said.
Novartis said it supported the decision.
"Cleary, patient safety is of the utmost importance," said Nick Kurstjens, the company's chief scientific officer for Australia.
Source: AFP
LIN/C
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.